Daiichi Says Pfizer Has Only Until July 7 To Bid For India’s Ranbaxy
This article was originally published in PharmAsia News
Executive Summary
U.S. drug maker Pfizer has until July 7 to make a competitive bid for Ranbaxy Laboratories of India, according to the current bidder, Japan's Daiichi Sankyo. Pfizer, which had not confirmed its interest, was reported to be considering a hostile bid for Ranbaxy, offering to buy the 65 percent share of the company not held by members of the family now controlling it. Under Indian law, Daiichi, which seeks to buy a controlling interest in Ranbaxy, must make a bid to buy an additional 20 percent of the company at the current share price. (Click here for more - a subscription may be required
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.